Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease. The ultimate goal of the study is to identify key biomarkers derived from blood that are most characteristic and informative of individuals who will go on to develop a clotting complication.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Philip S. Tsao, PhD
- Lawrence Leung
- George A. Fisher Jr.
- Lawrence "Rusty" Hofmann, MD
- Thomas Quertermous, MD
- Jeffrey Norton
- procedure : Observation
Ages Eligible For Study:
- Male or female, >= 18 years old. There are no ethnic restrictions. - Active cancers of the GI tract (gastroesophageal, colorectal, or pancreatic-biliary) that have completed TNM staging by the American Joint Committee on Cancer; stage III disease if diagnosed within 2 months and all stage IV disease - Ability to understand and the willingness to sign a written informed consent document. - Existing staging CT imaging study